Digitalis therapy is associated with higher comorbidities and poorer prognosis in patients undergoing ablation of atrial arrhythmias: data from the German Ablation Registry
| Autor: | Stefan G. Spitzer, Dierk Thomas, Stephan Willems, Gerrit Frommeyer, Jochen Senges, Thorsten Lewalter, Lars Eckardt, Matthias Hochadel, Johannes Brachmann, Petra Schirdewahn, Hüseyin Ince, Burghard Schumacher |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Male
medicine.medical_specialty medicine.medical_treatment Catheter ablation Digitalis Comorbidity Recurrence Internal medicine Germany Atrial Fibrillation medicine Prevalence Tachycardia Supraventricular Humans cardiovascular diseases Myocardial infarction Prospective Studies Registries Stroke Atrial tachycardia Aged biology business.industry Digitalis Glycosides Atrial fibrillation General Medicine Middle Aged biology.organism_classification medicine.disease Prognosis Atrial Flutter Heart failure cardiovascular system Cardiology Catheter Ablation Female medicine.symptom Cardiology and Cardiovascular Medicine business Anti-Arrhythmia Agents Atrial flutter Follow-Up Studies |
| Zdroj: | Clinical research in cardiology : official journal of the German Cardiac Society. 108(10) |
| ISSN: | 1861-0692 |
| Popis: | Digitalis glycosides are employed for rate control of atrial fibrillation. Recent studies suggested potential harmful effects of digitalis monotherapy and combination with antiarrhythmic drugs. The aim of the present study was to assess the prevalence and potential impact of digitalis therapy on outcome in patients undergoing catheter ablation of supraventricular arrhythmias. The German Ablation Registry is a nationwide, prospective registry with a 1-year follow-up investigating 12,566 patients receiving catheter ablations of supraventricular arrhythmias in 52 German centres. The present analysis focussed on pharmacotherapy in 8608 patients undergoing catheter ablation of atrial tachycardia, atrial fibrillation, or atrial flutter. Patients receiving digitalis therapy (n = 417) were older and presented a significantly increased prevalence of comorbidities including coronary artery disease, heart failure, diabetes, and pulmonary disease. One-year mortality was significantly higher in digitalis-treated patients (4.7% vs. 1.3%, p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink